Healthcare
Olympus Corporation(OLYMY)
Live Price
Offline$10.31
+3.10% today
1Y Change
-12.77%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $1.73T
- Revenue Growth
- +7.7%
- EPS Growth
- -48.5%
- Dividend Yield
- 1.9%
Coverage: 251 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Olympus Corporation (OLYMY) is a Healthcare stock with a market cap of $1.73T and listed on OTC. The stock last traded around $10.31 and down 12.8% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +7.7%, EPS growth of -48.5%, a dividend yield of 1.9%. What stands out right now is revenue +7.7%, EPS -48.5%, free cash flow 0.0% with operating margin 15.6% and ROIC 9.5%. The dividend is present but secondary, with a yield around 1.9%. Valuation is more restrained than many high-expectation growth names at P/E 20.4 and price/sales 1.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines OLYMY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+7.7% vs +7.6% peer median
Operating Margin
Below sector median
+15.6% vs +19.4% peer median
P/E
Below sector median
20.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +7.7% and EPS is at -48.5%, with operating margin around 15.6%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.9%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 2 reported quarters, the stock averaged -2.4% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +8.9% | +9.9% | +4.0% |
2026 Feb 13, 2026 | -43.7% | -9.6% | -14.7% | -25.0% |
Benchmark Edge
OLYMY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
OLYMY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
OLYMY Max Drawdown
-41.03%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for OLYMY and SPY.
Company Overview
Olympus Corporation
Other OTC
Olympus Corporation, together with its subsidiaries, manufactures and sells medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through Endoscopic Solutions Business, Therapeutic Solutions Business, and Other segments. The company offers gastrointestinal endoscopy system products comprising video endoscopy and ultrasound systems; GI endotherapy products consisting of CRC devices and HPB devices/hemostasis products; endoscopic solutions ecosystem products, including intelligent ecosystem operating software platforms, and AI insights and computer-aided detection/diagnosis products; reprocessing products, such as endoscope reprocessors, chemicals, accessories, and peripherals; and medical services, which include repair center services. It also provides respiratory products comprising bronchoscopy systems and devices, lung cancer products, and chronic obstructive pulmonary disease products; urology products consisting of visualization, stone management, benign prostatic hyperplasia (BPH), and BPH + bladder cancer products; surgical products, such as surgical endoscopy systems, advanced energy devices, surgical microscope, integrated procedure room solutions, and rhino-laryngoscopy systems, as well as surgical devices for the ears, nose, and throat; and gastroenterology devices and gynecology products. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was incorporated in 1919 and is headquartered in Hachioji, Japan.
- Leadership
- Frank Drewalowski
- IPO Date
- Nov 18, 1996
- Employees
- 29.3k
- Street Address
- 2951 Ishikawa-machi
- Mailing
- Hachioji, 192-8507
- Region
- Hachioji, JP
- Reporting Currency
- USD
- Investor Line
- 81 42 642 2111
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 20.4
- EV/EBITDA
- 8.1
- Price/Sales
- 1.8
- Price/Book
- 2.2
Growth
- Revenue
- +7.7%
- EPS
- -48.5%
- Free Cash Flow
- 0.0%
Profitability
- Gross Margin
- 66.2%
- Operating Margin
- 15.6%
- Net Margin
- 8.6%
- ROE
- 11.3%
- ROIC
- 9.5%
Balance Sheet
- Debt/Equity
- 0.31
- Current Ratio
- 1.63
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.